Acute leukemia immunohistochemistry: A systematic diagnostic approach

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 3, 2008, Pages 462-475

  Olsen, Randall J ^a   Chang, Chung Che ^a   Herrick, Jennifer L ^b   Zu, Youli ^a   Ehsan, Aamir ^c  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; B LYMPHOCYTE ANTIGEN; BLOOD CLOTTING FACTOR 8; CD15 ANTIGEN; CD163 ANTIGEN; CD2 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD3 ANTIGEN; CD31 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD61 ANTIGEN; CD68 ANTIGEN; CD7 ANTIGEN; CD79A ANTIGEN; CD8 ANTIGEN; DENILEUKIN DIFTITOX; FIBRINOGEN RECEPTOR; GEMTUZUMAB OZOGAMICIN; HEMOGLOBIN A; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN M; LYSOZYME; PROTEIN BCL 6; RITUXIMAB; T LYMPHOCYTE ANTIGEN; T6 ANTIGEN; TOSITUMOMAB; TRANSCRIPTION FACTOR PAX5;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; B LYMPHOCYTE; BONE MARROW CELL; CELL LINEAGE; CYTOCHEMISTRY; ERYTHROID CELL; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; LYMPHATIC LEUKEMIA; LYMPHOBLASTOMA; MEDLINE; MONOCYTE; MYELOID LEUKEMIA; REVIEW; SKIN HEMANGIOMA; T LYMPHOCYTE;

ACUTE DISEASE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA; TUMOR MARKERS, BIOLOGICAL;

EID: 40349100451     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Berman L. Malignant lymphomas, their classification and relation to leukemia. Blood. 1953;8:195-210.
2. Thiele J, Kvasnicka HM, Vardiman J. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl. Best Pract Res Clin Haematol. 2006;19:413-437.
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) Co-operative Group. Br J Haematol. 1976;33:451-458.
4. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
5. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. World Health Organization Classification of Tumours; vol 3.
6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) Classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
7. Stam RW, den Boer ML, Pieters R. Towards targeted therapy for infant acute lymphoblastic leukaemia. Br J Haematol. 2006;132:539-551.
8. Tefferi A, Dewald GW, Litzow ML, et al. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clin Proc. 2005;80:390-402.
9. Kroft SH. Role of flow cytometry in pediatric hematopathology. Am J Clin Pathol. 2004;122(suppl):S19-S32.
10. Dunphy CH. Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. Arch Pathol Lab Med. 2006;130:483-520.
11. van der Valk P, Mullink H, Huijgens PC, Tadema TM, Vos W, Meijer CJ. Immunohistochemistry in bone marrow diagnosis: value of a panel of monoclonal antibodies on routinely processed bone marrow biopsies. Am J Surg Pathol. 1989; 13:97-106.
12. Taubenberger JK, Cole DE, Raffeld M, Poplack DG, Jaffe ES, Medeiros LJ. Immunophenotypic analysis of acute lymphoblastic leukemia using routinely processed bone marrow specimens. Arch Pathol Lab Med. 1991;115:338-342.
13. Arber DA, Jenkins KA. Paraffin section immunophenotyping of acute leukemias in bone marrow specimens. Am J Clin Pathol. 1996;106:462-468.
14. Herman GE, Elfont EA, Floyd AD. Overview of automated immunostainers. Methods Mol Biol. 1994;34:383-403.
15. Cuevas EC, Bateman AC, Wilkins BS, et al. Microwave antigen retrieval in immunocytochemistry: a study of 80 antibodies. J Clin Pathol. 1994;47:448-452.
16. Blumenthal D, Gluck M, Louis KS, Stoto MA, Wise D. University-industry research relationships in biotechnology: implications for the university. Science. 1986;232:1361-1366.
17. Keren DF, McCoy JP, Carey JL. Flow Cytometry in Clinical Diagnosis. 3rd ed. Chicago, III: American Society of Clinical Pathology Press; 2001:739.
18. Gosling PT, Gemmell E, Carter CL, Bird PS, Seymour GJ. Immunohistological analysis of Tannerella forsythia-induced lesions in a murine model. Oral Microbiol Immunol. 2005;20:25-30.
19. Schmid I, Ferbas J, Uittenbogaart CH, Giorgi JV. Flow cytometric analysis of live cell proliferation and phenotype in populations with low viability. Cytometry. 1999;35:64-74.
20. Neame PB, Soamboonsrup P, Browman GP, et al. Classifying acute leukemia by immunophenotyping: a combined FAB-immunologic classification of AML. Blood. 1986;68:1355-1362.
21. Vega F, Chang CC, Medeiros LJ, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005;18:806-815.
22. Chu PG, Loera S, Huoang O, Weiss LM. Lineage determination of CD20-B-cell neoplasms: an immunohistochemical study. Am J Clin Pathol. 2006;126: 534-544.
23. Gibson SE, Dong HY, Advani AS, His ED. Expression of the B cell-associated transcription factors PAX5, OCT-2, and BOB.1 in acute myeloid leukemia: associations with B-cell antigen expression and myelomonocytic maturation. Am J Clin Pathol. 2006;126:916-924.
24. Cattoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal center B-cells. Blood. 1995;86:45-53.
25. Pittaluga S, Ayoubi TA, Wlodarska I, et al. BCL-6 expression in reactive lymphoid tissue and in B-cell NHLs. J Pathol. 1996;179:145-150.
26. Lewis RE, Cruse JM, Sanders CM, et al. The immunophenotype of pre-TALL/LBL revisited. Exp Mol Pathol. 2006;81:162-165.
27. Li S, Juco J, Mann KP, Holden JT. Flow cytometry in the differential diagnosis of lymphocyte-rich thymoma from precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. Am J Clin Pathol. 2004;121:268-274.
28. Reuss-Borst MA, Buhring HJ, Schmidt H, Muller CA. AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. Leukemia. 1994;8:258-263.
29. Vaughan WP, Civin CI, Weisenburger DD, etal. Acute leukemia expressing the normal human hematopoietic stem cell membrane glycoprotein CD34 (MY10). Leukemia. 1988;2:661-666.
30. Steen R, Tjonnfjord GE, Gaudernack G, Brinch L, Egeland T. Differences in the distribution of CD34 epitopes on normal haemopoietic progenitor cells and leukaemic blast cells. Br J Haematol. 1996;94:597-605.
31. Manaloor EJ, Neiman RS, Heilman DK, et al. Immunohistochemistry can be used to subtype acute myeloid leukemia in routinely processed bone marrow biopsy specimens: comparison with flow cytometry. Am J Clin Pathol. 2000;113: 814-822.
32. Matutes E, Morula R, Farahat N, et al. Definition of acute biphenotypic leukemia. Haematologica. 1997;82:64-66.
33. Akashi K, Shibuya T, Harada M, et al. Acute 'bilineal-biphenotypic' leukaemia. Br J Haematol. 1990;74:402-407.
34. Zomas AP, Swansbury GJ, Matutes E, et al. Bilineal acute leukemia of B and T lineage with a novel translocation t(9;17)(p11;q11). Leuk Lymphoma. 1997; 25:179-185.
35. Frater JL, Yaseen NR, Peterson LC, Tallman MS, Goolsby CL. Biphenotypic acute leukemia with coexpression of CD79a and markers of myeloid lineage. Arch Pathol Lab Med. 2003;127:356-359.
36. Lau LG, Tan LK, Koay ES, Ee MH, Tan SH, Liu TC. Acute lymphoblastic leukemia with the phenotype of a putative B-cell/T-cell bipotential precursor. Am J Hematol. 2004;77:156-160.
37. Owaidah TM, Al Beihany A, Iqbal MA, Elkum N, Roberts GT. Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system. Leukemia. 2006;20:620-626.
38. Boldt DH, Kopecky KJ, Head D, et al. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults: the Southwest Oncology Group experience. Leukemia. 1994;8:2118-126.
39. Albano F, Mestice A, Pannunzio A, et al., The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes. Haematologica. 2006;91: 311-316.
40. Biondi A, Luciano A, Bassan R, et al. CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint. Leukemia. 1995;9:1461-1466.
41. Bene MC, Castoldi G, Knapp W, et al, European Group for the Immunological Characterization of Leukemias (EGIL). Proposals for the immunological classification of acute leukemias. Leukemia. 1995;9:1783-1786.
42. EGIL (European Group for the Immunologic Classification of Leukaemias). The value of c-kit in the diagnosis of biphenotypic acute leukemia. Leukemia. 1998;12:2038.
43. Adriaansen HJ, Soeting PW, Wolvers-Tetterro IL, et al. Immunoglobulin and T-cell receptor gene rearrangements in acute non-lymphocytic leukemias: analysis of 54 cases and a review of the literature. Leukemia. 1991;5:744-751.
44. Petrella T, Dalac S, Maynadie M, et al, Groupe Française d'Etude des Lymphomes Cutanés (GFELC). CD4+, CD56+ cutaneous neoplasms: a distinct hematological entity? Am J Surg Pathol. 1999;23:137-146.
45. Munoz L, Nomdedeu JF, Lopez O, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001; 86:1261-1269.
46. Feuillard J, Jacob MC, Valensi F, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;99:1556-1563.
47. Jacob MC, Chaperot L, Mossuz P, et al. CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica. 2003;88:941-955.
48. Reichard KK, Burks EJ, Foucar MK, et al. CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol. 2005;29:1274-1283.
49. Nava VE, Jaffe ES. The pathology of NK-cell lymphomas and leukemias. Adv Anat Pathol. 2005;12:27-34.
50. Li CY, Yam LT. Cytochemistry and immunochemistry in hematologic diagnoses. Hematol Oncol Clin North Am. 1994;8:665-681.
51. Pervez S, Khurshid M. Classification and immunophenotyping of acute leukemias: a prospective study. J Pak Med Assoc. 1997;47:103-106.
52. Rizzatti EG, Garcia AB, Portieres FL, Silva DE, Martins SL, Falcao RP. Expression of CD117 and CD11b in bone marrow can differentiate acute promyelocytic leukemia from recovering benign myeloid proliferation. Am J Clin Pathol. 2002;118:31-37.
53. Paietta E, Ferrando AA, Neuberg D, et al. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood. 2005;106:4414-4415.
54. Baek JY, Tefferi A, Pardanani A, Li CY. Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease. Leuk Res. 2002;26:83-90.
55. Jordan JH, Walchshofer S, Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol. 2001;32:545-552.
56. Meenan B, Heavey C, Lichtenstein A, Andersen J, Paietta E, Eastern Cooperative Oncology Group. Terminal transferase expression in the differential diagnosis of acute leukemias. Leuk Lymphoma. 1996;22:265-269.
57. Suzumiya J, Ohshima K, Kikuchi M, Takeshita M, Akamatsu M, Tashiro K. Terminal deoxynucleotidyl transferase staining of malignant lymphomas in paraffin sections: a useful method for the diagnosis of lymphoblastic lymphoma. J Pathol. 1997;182:86-91.
58. Bluestone JA, Pardoll D, Sharrow SO, Fowlkes BJ. Characterization of murine thymocytes with CD3-associated T-cell receptor structures. Nature. 1987; 326:82-84.
59. Janossy G, Coustan-Smith E, Campana D. The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases. Leukemia. 1989;3:170-181.
60. Ohno T, Yamaguchi M, Oka K, Miwa H, Kita K, Shirakawa S. Frequent expression of CD3 epsilon in CD3 (Leu 4)-negative nasal T-cell lymphomas. Leukemia. 1995;9:44-52.
61. Mason DY, Cordell JL, Brown MH, et al. CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples. Blood. 1995;86:1453-1459.
62. Buccheri V, Mihaljevic B, Matutes E, Dyer MJ, Mason DY, Catovsky D. mb-1: a new marker for B-lineage lymphoblastic leukemia. Blood. 1993;82:853-857.
63. Torlakovic E, Torlakovic G, Nguyen PL, Brunning RD, Delabie J. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol. 2002;26:1343-1350.
64. Valbuena JR, Medeiros LJ, Rassidakis GZ, et al. Expression of B cell-specific activator protein/PAX5 in acute myeloid leukemia witht(8;21)(q22;q22). Am J Clin Pathol. 2006;126:235-240.
65. Asnafi V, Beldjord K, Garand R, et al. IgH DJ rearrangements within T-ALL correlate with cCD79a expression, an immature/TCRγδ phenotype and absence of IL7Rα/CD127 expression. Leukemia. 2004;18:1997-2001.
66. Chuang SS, Li CY. Useful panel of antibodies for the classification of acute leukemia by immunohistochemical methods in bone marrow trephine biopsy specimens. Am J Clin Pathol. 1997;107:410-418.
67. Pinkus GS, Pinkus JL. Myeloperoxidase: a specific marker for myeloid cells in paraffin sections. Mod Pathol. 1991;4:733-741.
68. Kebriaei P, Anastasi J, Larson RA. Acute lymphoblastic leukaemia: diagnosis and classification. Best Pract Res Clin Haematol. 2002;15:597-621.
69. Arber DA, Snyder DS, Fine M, Dagis A, Niland J, Slovak ML. Myeloperoxidase immunoreactivity in adult acute lymphoblastic leukemia. Am J Clin Pathol. 2001;116:25-33.
70. Matano S, Terahata S, Nakamura S, Kobayashi K, Sugimoto T. CD56-positive acute lymphoblastic leukemia. Acta Haematol. 2005;114:160-163.
71. Kroschinsky F, Friedrich K, Hanel M, et al. Extramedullar blast crisis of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation mimicking aggressive, translocation t(14;18)-positive B-cell lymphoma. Ann Hematol. 2003;82:47-52.
72. Kennedy GA, Cull G, Gill D, Marlton P, Norris D, Cobcroft R. Identification of tumours with the CD43 only phenotype during the investigation of suspected lymphoma: a heterogeneous group not necessarily of T cell origin. Pathology. 2002;34:46-50.
73. Brouwer RE, Hoefnagel J, Borger van Der Burg B, et al. Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis. Br J Haematol. 2001;115:298-308.
74. Hyjek E, Chadburn A, Liu YF, Cesarman E, Knowles DM. BCL-6 protein is expressed in precursor T-cell lymphoblastic lymphoma and in prenatal and post-natal thymus. Blood 2001;97:270-276.
75. Horny HP, Campbell M, Steinke B, Kaiserling E. Acute myeloid leukemia: immunohistologic findings in paraffin-embedded bone marrow biopsy specimens. Hum Pathol. 1990;21:648-655.
76. Cohen PL, Hoyer JD, Kurtin PJ, Dewald GW, Hanson CA. Acute myeloid leukemia with minimal differentiation: a multiple parameter study. Am J Clin Pathol. 1998;109:32-38.
77. Toth B, Wehrmann M, Kaiserling E, Horny HP. Immunophenotyping of acute lymphoblastic leukaemia in routinely processed bone marrow biopsy specimens. J Clin Pathol. 1999;52:688-692.
78. Chang CC, Eshoa C, Kampalath B, Shidham VB, Perkins S. Immunophenotypic profile of myeloid cells in granulocytic sarcoma by immunohistochemistry: correlation with blast differentiation in bone marrow. Am J Clin Pathol. 2000;114:807-811.
79. Lau SK, Chu PG, Weiss LM. CD163 A specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol. 2004;122:794-801.
80. Falini B, Flenghi L, Pileri S, et al. PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule. Am J Pathol. 1993;142:1359-1372.
81. Walter RB, Bachli EB, Schaer DJ, et al. Expression of the hemoglobin scavenger receptor (CD163/HbSR) as immunophenotypic marker of monocytic lineage in AML. Blood 2003;101:3755-3756.
82. Soslow RA, Bhargava V, Warnke RA. MIC2, TdT, bcl-2, and CD34 expression in paraffin-embedded high-grade lymphoma/acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entities. Hum Pathol. 1997;28: 1158-1165.
83. Ozdemirli M, Fanburg-Smith JC, Hartmann DP, Azumi N, Miettinen M. Differentiating lymphoblastic lymphoma and Ewing's sarcoma: lymphocyte markers and gene rearrangement. Mod Pathol. 2001;14:1175-1182.
84. Lucas DR, Bentley G, Dan ME, Tabaczka P, Poulik JM, Mott MP. Ewing sarcoma vs lymphoblastic lymphoma: a comparative immunohistochemical study. Am J Clin Pathol. 2001;115:11-17.
85. Ruck P, Horny HP, Greschniok A, Wehrmann M, Kaiserling E. Nonspecific immunostaining of blast cells of acute leukemia by antibodies against nonhemopoietic antigens. Hematol Pathol. 1995;9:49-56.
86. Kontogianni K, Nicholson AG, Butcher D, Sheppard MN. CD56: a useful tool for the diagnosis of small cell lung carcinomas on biopsies with extensive crush artefact. J Clin Pathol. 2005;58:978-980.
87. Blumke K, Bilkenroth U, Schmidt U, et al. Detection of circulating tumor cells from renal carcinoma patients: experiences of a two-center study. Oncol Rep. 2005;14:895-899.
88. Bouma-ter Steege JC, Baeten CI, Thijssen VL, et al. Angiogenic profile of breast carcinoma determines leukocyte infiltration. Clin Cancer Res. 2004;10: 7171-7178.
89. Gokbuget N, Hoelzer D. Novel antibody-based therapy for acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2006;19:701-713.
90. Thachil J, Mukherje K, Woodcock B. Rituximab-induced haemorrhagic thrombocytopenia in a patient with hairy cell leukaemia. Br J Haematol. 2006; 135:273-274.
91. Claviez A, Eckert C, Seeger K, et al. Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia. Haematologica. 2006;91:272-273.
92. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyperCVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569-1580.
93. Fenton C, Perry CM. Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia. Drugs. 2005;65:2405-2427.
94. van der Heiden PL, Jedema I, Willemze R, Barge RM. Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Eur J Haematol. 2006;76:409-413.
95. Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005;106:454-457.
96. Frankel AE, Surendranathan A, Black JH, White A, Ganjoo K, Cripe LD. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer. 2006; 106:2158-2164.
97. Robak T. Alemtuzumab in the treatment of chronic lymphocytic leukemia. BioDrugs. 2005;19:9-22.
98. Reineke T, Jenne B, Abdou MT, et al. Ultrasonic decalcification offers new perspectives for rapid FISH, DNA, and RT-PCR analysis in bone marrow trephines. Am J Surg Pathol. 2006;30:892-896.
99. Murthy SK, Demetrick DJ. New approaches to fluorescence in situ hybridization. Methods Mol Biol. 2006;319:237-259.
100. Rowe LR, Willmore-Payne C, Tripp SR, et al. Tumor cell nuclei extraction from paraffin-embedded lymphoid tissue for fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol. 2006;14:220-224.
101. Sharma JS, Mohindroo S. FAB classification of leukemia: a cytochemical study. Indian J Pathol Microbiol. 2004;47:336-339.
102. Mhawech P, Buffone GJ, Khan SP, Gresik MV. Cytochemical staining and flow cytometry methods applied to the diagnosis of acute leukemia in the pediatric population: an assessment of relative usefulness. J Pediatr Hematol Oncol. 2001;23:89-92.
103. Elghetany MT, MacCallum JM, Davey FR. The use of cytochemical procedures in the diagnosis and management of acute and chronic myeloid leukemia. Clin Lab Med. 1990;10:707-720.
104. Anand M, Ghara N, Kumar R, et al. Myeloperoxidase cytochemical negativity: an unexpected but intrinsic property of blasts of all phases of chronic myeloid leukemia. Ann Hematol. 2005;84:767-770.
105. Peffault de Latour R, Legrand O, Moreau D, et al. Comparison of flow cytometry and enzyme cytochemistry for the detection of myeloperoxidase in acute myeloid leukaemia: interests of a new positivity threshold. Br J Haematol. 2003;122:211-216.
106. McKenna RW, Bloomfield CD, Dick F, Nesbit ME, Brunning RD. Acute monoblastic leukemia: diagnosis and treatment of ten cases. Blood. 1975;46: 481-494.
107. da Fonseca LM, Brunetti IL, Campa A, Catalani LH, Calado RT, Falcao RP. Assessment of monocytic component in acute myelomonocytic and monocytic/monoblastic leukemias by a chemiluminescent assay. Hematol J. 2003;4: 26-30.
108. Drexler HG, Gaedicke G, Hoffbrand AV, Minowada J. Occurrence of particular isoenzymes in fresh and cultured leukemia-lymphoma cells, III: esterase isoenzyme in monocytes. Cancer. 1987;59:77-82.
109. Snower DP, Smith BR, Munz UJ, McPhedran P. Reevaluation of the periodic acid-Schiff stain in acute leukemia with immunophenotypic analyses. Arch Pathol Lab Med. 1991;115:346-350.
110. Crogan TM, Warnke RA, Kaplan HS. A comparative study of Burkitt's and non-Burkitt's "undifferentiated" malignant lymphoma: immunologic, cytochemical, ultrastructural, cytologic, histopathologic, clinical and cell culture features. Cancer. 1982;49:1817-1828.